Please marijuana was not made illegal because of Mexican immigrants. it was made illegal because chemical company's lobbied against it so it couldn't compete against their products. If they just didn't want you to smoke it why would they make industrial hemp Illegal.
The research is getting much better, still a lot of red tape. CARA pharmy is a new up and comer. I'm an investor, so may be biased...but:
Cara Therapeutics doesn't have any products on the market yet, so the company's financial position isn't as solid as the other two on our list. And while Cara's pipeline includes cannabis-based research, the company's future isn't as tightly linked to the medical marijuana industry as either GW Pharmaceuticals or Insys.
Pain medication CR845 is Cara's lead candidate. The company expects to report results from a late-stage clinical study of the kappa opioid receptor drug in treating post-operative pain in the first half of 2017. The potential for CR845 is great, because the drug can relieve pain without causing the addictive qualities associated with many existing opioid drugs. https://www.fool.com/investing/general/2015/07/10/3-marijuana-stocks-to-watch.aspx
Thank you for the very informative video. Medical marijuana has had a lot of controversy surrounding it and the more information that can be shared to the public, the more likely the government may change it from a scheduled I drug to a scheduled II. Keep up the good work!
Please marijuana was not made illegal because of Mexican immigrants. it was made illegal because chemical company's lobbied against it so it couldn't compete against their products. If they just didn't want you to smoke it why would they make industrial hemp Illegal.
Downvoting a post can decrease pending rewards and make it less visible. Common reasons:
Submit
The research is getting much better, still a lot of red tape. CARA pharmy is a new up and comer. I'm an investor, so may be biased...but:
Cara Therapeutics doesn't have any products on the market yet, so the company's financial position isn't as solid as the other two on our list. And while Cara's pipeline includes cannabis-based research, the company's future isn't as tightly linked to the medical marijuana industry as either GW Pharmaceuticals or Insys.
Pain medication CR845 is Cara's lead candidate. The company expects to report results from a late-stage clinical study of the kappa opioid receptor drug in treating post-operative pain in the first half of 2017. The potential for CR845 is great, because the drug can relieve pain without causing the addictive qualities associated with many existing opioid drugs.
https://www.fool.com/investing/general/2015/07/10/3-marijuana-stocks-to-watch.aspx
Downvoting a post can decrease pending rewards and make it less visible. Common reasons:
Submit
Thank you for the very informative video. Medical marijuana has had a lot of controversy surrounding it and the more information that can be shared to the public, the more likely the government may change it from a scheduled I drug to a scheduled II. Keep up the good work!
Downvoting a post can decrease pending rewards and make it less visible. Common reasons:
Submit
The tide appears to be shifting in that direction.
Downvoting a post can decrease pending rewards and make it less visible. Common reasons:
Submit
I hope that it does!
Downvoting a post can decrease pending rewards and make it less visible. Common reasons:
Submit